Loading…
Loading…
MASI (Masimo Corporation) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MASI and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MASI and 80,000+ other tickers.
See exactly how MASI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MASI and 80,000+ other tickers.
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring…
IRVINE, Calif.--(BUSINESS WIRE)-- #Masimo--Masimo smartSET™-powered, AI-enabled OIRD detection has received FDA 510(k) clearance for the Radius VSM® wearable continuous patient monitor.
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026 (the “Merger Agreement”), by and among Masimo, Danaher Corporation (“Danaher”) (NYSE: DHR) and Mobius Merger Sub, Inc. (the “Merger Sub”) at Masimo's special meeting of stockholders held virtually on May 1, 2026 (.
MASI's SET pulse oximetry shows accurate, consistent readings in hospitalized newborns across all skin tones in the largest real-world study.